Tonix Pharmaceuticals Holding Corp - Asset Resilience Ratio
Tonix Pharmaceuticals Holding Corp (TNXP) has an Asset Resilience Ratio of 0.62% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Tonix Pharmaceuticals Holding Corp to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2017)
This chart shows how Tonix Pharmaceuticals Holding Corp's Asset Resilience Ratio has changed over time. See how leveraged is Tonix Pharmaceuticals Holding Corp's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Tonix Pharmaceuticals Holding Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see TNXP market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $99.00K | 0.62% |
| Total Liquid Assets | $99.00K | 0.62% |
Asset Resilience Insights
- Limited Liquidity: Tonix Pharmaceuticals Holding Corp maintains only 0.62% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tonix Pharmaceuticals Holding Corp Industry Peers by Asset Resilience Ratio
Compare Tonix Pharmaceuticals Holding Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Tonix Pharmaceuticals Holding Corp (2012–2017)
The table below shows the annual Asset Resilience Ratio data for Tonix Pharmaceuticals Holding Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 26.84% | $7.18 Million | $26.75 Million | +0.74pp |
| 2016-12-31 | 26.10% | $7.18 Million | $27.51 Million | -24.61pp |
| 2015-12-31 | 50.71% | $23.84 Million | $47.02 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $39.54 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $8.74 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $2.12 Million | -- |
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and T… Read more